US Stock MarketDetailed Quotes
CAPR Capricor Therapeutics
- 5.410
- +0.260+5.05%
Close Apr 26 16:00 ET
- 5.530
- +0.120+2.22%
Post 18:52 ET
170.43MMarket Cap-6518P/E (TTM)
5.490High5.120Low639.21KVolume5.140Open5.150Pre Close3.41MTurnover2.45%Turnover RatioLossP/E (Static)31.50MShares8.22152wk High7.55P/B141.27MFloat Cap2.68052wk Low--Dividend TTM26.11MShs Float7999.998Historical High--Div YieldTTM7.18%Amplitude0.880Historical Low5.334Avg Price1Lot Size
Capricor Therapeutics Stock Forum
Sign in to post a comment
Update
$Capricor Therapeutics(CAPR.US$ Capricor Therapeutics Announces Positive Type-B Meeting With FDA for Cap-1002 Program for Duchenne Muscular Dystrophy
1
Update
$Capricor Therapeutics(CAPR.US$ Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
4 MINUTES AGO, 8:30 AM EST
VIA GLOBENEWSWIRE
4 MINUTES AGO, 8:30 AM EST
VIA GLOBENEWSWIRE
$Capricor Therapeutics(CAPR.US$ we'll. see $5.34 soon.
1
Investors' expectations of limited future growth may be causing the low P/S ratio. These conditions form a barrier for the share price unless improved. Consider other vital risk factors before investing in Capricor Therapeutics.
Update
$Capricor Therapeutics(CAPR.US$Moomoo 24/7· just. Capricor Therapeutics Receives First Milestone Payment Of $10M From Nippon Shinyaku, Co. Under Exclusive Commercialization And Distribution Agreement
Capricor Therapeutics is anticipated to see limited growth in the future, keeping its P/S ratio low. Despite recent growth, its muted future outlook compared to the overall industry could remain a barrier for its share price.
Watching closely!
$Capricor Therapeutics(CAPR.US$ Looking for lots of updates/PR on a couple of their drug trials before EOY
UPDATE!
$Capricor Therapeutics(CAPR.US$ Item 7.01
Regulation FD Disclosure.
On September 29, 2023, the Company announced a positive outcome from a Type-B clinical meeting with the U.S. Food and Drug Administration (the “FDA”) on the design and execution of HOPE-3, the Phase 3 pivotal trial of CAP-1002 in Duchenne Muscular Dystrophy (“DMD”). Feedback from the FDA on the proposed key clinical and regulatory requirements confirms CAP-1002’s path towards Biologics License Application (“BLA”) submiss...
Regulation FD Disclosure.
On September 29, 2023, the Company announced a positive outcome from a Type-B clinical meeting with the U.S. Food and Drug Administration (the “FDA”) on the design and execution of HOPE-3, the Phase 3 pivotal trial of CAP-1002 in Duchenne Muscular Dystrophy (“DMD”). Feedback from the FDA on the proposed key clinical and regulatory requirements confirms CAP-1002’s path towards Biologics License Application (“BLA”) submiss...
1
$Capricor Therapeutics(CAPR.US$ today runner
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
TrytosaveabitOP : Capricor Therapeutics Inc: Granted Subsequent Type-B Clinical Meeting With FDA in Q2 to Continue to Discuss Pathway to Bla